| Wang, Hong |
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
| Completed | 3 | 257 | RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases | 07/24 | 07/24 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
|
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
NCT05520177: A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss |
|
|
| Recruiting | 3 | 350 | RoW | 601 1.25mg, 601, ranibizumab 0.5mg, Lucentis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Branch Retinal Vein Occlusion | 12/25 | 12/25 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 71 | RoW | TQ-B3139 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 01/22 | 10/22 | | |
NCT06212297: Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy |
|
|
| Recruiting | 1/2 | 9 | RoW | LX101 | Innostellar Biotherapeutics Co.,Ltd | Inherited Retinal Dystrophy | 09/24 | 03/29 | | |
NCT04458389: A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas |
|
|
| Recruiting | 1/2 | 268 | RoW | TY101 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Locally Advanced /Metastatic Solid Tumors, Relapsed or Refractory Lymphomas | 06/24 | 07/25 | | |
| Completed | 1 | 46 | RoW | CM326, Placebo | Keymed Biosciences Co.Ltd | Healthy | 10/23 | 10/23 | | |
| Recruiting | 1 | 40 | RoW | ZL-82, 600mg ZL-82, 50mg ZL-82, 100mg ZL-82, 200mg ZL-82, ZL-82 placebo, 600mg ZL-82 placebo, 50mg ZL-82 placebo, 100mg ZL-82 placebo, 200mg ZL-82 placebo | Chengdu Zenitar Biomedical Technology Co., Ltd | Healthy Person | 08/24 | 12/24 | | |
NCT05702450: Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310 |
|
|
| Completed | 1 | 240 | RoW | CM310 | Keymed Biosciences Co.Ltd | Healthy | 07/23 | 07/23 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Badhwar, Vinay |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 05/24 | 06/28 | | |
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment |
|
|
| Active, not recruiting | N/A | 150 | US | AtriCure CryoICE & AtriClip LAA Exclusion | AtriCure, Inc. | Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation | 06/24 | 06/26 | | |
| Roberts, Harold |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
| Lindsey, Brock |
| Terminated | N/A | 234 | US | Tritanium® Primary Acetabular Shell | Stryker Orthopaedics | Arthroplasty, Replacement, Hip | 05/22 | 12/23 | | |
| Dietz, Matthew J |
NCT04238819: A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma |
|
|
| Active, not recruiting | 1/2 | 117 | Europe, Japan, US, RoW | Abemaciclib, LY2835219, Irinotecan, Temozolomide, Dinutuximab, GM-CSF | Eli Lilly and Company | Relapsed Solid Tumor, Refractory Solid Tumor | 03/24 | 04/25 | | |
MAGIC, NCT05361941: Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth In/near Infected Bone Cavities |
|
|
| Recruiting | N/A | 204 | US | EP Granules with Tobramycin, empty voids | Elute, Inc. | Periprosthetic Joint Infections | 12/25 | 12/25 | | |
| Eicher, Jennifer |
| Withdrawn | 2 | 90 | US | Bacteriophage, Placebo | Adaptive Phage Therapeutics, Inc. | Prosthetic Joint Infection | 07/25 | 07/27 | | |
MAGIC, NCT05361941: Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth In/near Infected Bone Cavities |
|
|
| Recruiting | N/A | 204 | US | EP Granules with Tobramycin, empty voids | Elute, Inc. | Periprosthetic Joint Infections | 12/25 | 12/25 | | |
NCT05405374: OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study |
|
|
| Recruiting | N/A | 101 | US | OSTEOAMP, Infuse | Bioventus LLC | Lumbar Spine Disease, Lumbar Spondylolisthesis, Lumbar Spine Instability, Lumbar Spondylosis, Degenerative Disc Disease | 10/24 | 10/25 | | |
| Recruiting | N/A | 1017 | US, RoW | Infuse™ Bone Graft (Infuse™), Intervertebral body fusion device and Medtronic posterior Fixation Systems | Medtronic Spinal and Biologics | Degenerative Disease of the Lumbosacral Spine | 04/26 | 04/28 | | |
NCT05339594: REINVENT Registry (Registry of the Nerve Gap Repair From Integra) |
|
|
| Terminated | N/A | 17 | US | NeuraGen, NeuraGen 3D | Integra LifeSciences Corporation | Peripheral Nerve Injuries | 06/24 | 06/24 | | |
| Sampson, Shannon |
NCT05248997: Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis |
|
|
| Completed | 3 | 261 | US | rimegepant 75 mg ODT, Matching placebo | Pfizer, Biohaven Pharmaceutical Holding Company Ltd. | Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps | 03/24 | 04/24 | | |
| Remy, Kenneth |
NCT05354141: Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS) |
|
|
| Recruiting | 3 | 970 | US | ExoFlo, Intravenous normal saline | Direct Biologics, LLC | Acute Respiratory Distress Syndrome, ARDS | 03/25 | 08/25 | | |
REITAB-2, NCT05204563: Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, ) |
|
|
| Recruiting | 3 | 450 | Europe, US, RoW | Combination of Imipenem/Cilastatin and XNW4107, Imipenem/Cilastatin/Relebactam, Recarbrio | Evopoint Biosciences Inc. | Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia | 04/25 | 12/25 | | |
| Recruiting | 2 | 150 | US | Auxora, Placebo | CalciMedica, Inc. | Acute Kidney Injury | 08/25 | 08/25 | | |
| Law, Kari |
| No trials found |
